Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
This book provides unique insights into the issues that drive modified dosing regimens for antibiotics in the critically ill. Leading international authors provide their commentary alongside a summary of existing evidence on how to effectively dose antibi
- PDF / 4,873,446 Bytes
- 279 Pages / 439.43 x 683.15 pts Page_size
- 64 Downloads / 216 Views
Antibiotic Pharmacokinetic/ Pharmacodynamic Considerations in the Critically Ill
Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
Andrew A. Udy • Jason A. Roberts • Jeffrey Lipman Editors
Antibiotic Pharmacokinetic/ Pharmacodynamic Considerations in the Critically Ill
Editors Andrew A. Udy Australian and New Zealand Intensive Care Research Centre School of Public Health and Preventive Medicine, Monash University Melbourne Victoria Australia
Jason A. Roberts Burns, Trauma and Critical Care Research Centre The University of Queensland UQ Centre for Clinical Research Herston Queensland Australia
Jeffrey Lipman Burns, Trauma and Critical Care Research Centre The University of Queensland Herston Queensland Australia
ISBN 978-981-10-5335-1 ISBN 978-981-10-5336-8 (eBook) DOI 10.1007/978-981-10-5336-8 Library of Congress Control Number: 2017952539 © Springer Nature Singapore Pte Ltd. 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Adis imprint is published by Springer Nature The registered company is Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore
Preface
Sepsis continues to be a major cause of morbidity and mortality worldwide. In the United States alone, sepsis accounts for 210,000 deaths annually, at a cost of $17 billion [1]. However this represents only a fraction of the global burden of this syndrome, with an estimated 15–19 million cases per year—the vast majority of which occur in low income countries [2]. Albeit there has been significant investment in developing clinical protocols and guidelines [3], and assessing novel pharmacological interventions [4], 28-day mortality from sepsis in high income countries remains around 20–25% [5, 6]. In addition to short-term mortality, septic patient
Data Loading...
